

# INVITATION

22 September 2024

Clinical Symposium at TTS 2024

## ECP after solid organ transplantation: Possible role in ABMR and presentation of patient cases

Istanbul Congress Center, Turkey

This information is intended for healthcare professionals in Europe and the Middle East

### Agenda

**Time: 14:00 – 15:00**

<b>Moderator</b>	<b>Prof. James Hutchinson</b> , University Hospital Regensburg, Germany
14:00 – 14:05	<b>Introduction</b> <b>Prof. James Hutchinson</b> , University Hospital Regensburg, Germany
14:05 – 14:15	<b>How ECP may benefit HTX patients now and in the future</b> <b>Prof. Markus Barten</b> , University Heart & Vascular Center Hamburg, Germany
14:15 – 14:25	<b>The potential role of ECP in prevention of complications post lung transplant</b> <b>Prof. Peter Jaksch</b> , Medical University Vienna, Austria
14:25 – 14:50	<b>Discussion of four patient cases</b> All
14:50 – 15:00	<b>Q&amp;A</b>

*ECP: Extracorporeal Photopheresis, ABMR: Antibody Mediated Rejection, HTX: Heart Transplantation*

*All speakers subject to contract.*

***This is a commercial programme run by Therakos (UK) Ltd,  
a Mallinckrodt Company.***

[Privacy policy](#)

Follow the  
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit [www.therakos.eu](http://www.therakos.eu)  
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt  
company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2024 Mallinckrodt. EU-2400195 June 2024.

*Although we have determined that we have a legitimate interest in using your data for marketing  
and sales purposes as per the terms of the current data protection legislation, you can opt-out  
by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides  
additional information.*